Goldman-Backed Biotech Attovia Raises $289 Million in US IPO

Attovia Therapeutics Inc., an early-stage biopharmaceutical company dedicated to developing novel treatments for immune system diseases with high unmet medical needs, has successfully raised $289 million through its initial public offering (IPO) on a US stock exchange. The company's shares were priced at $19 each, representing the top end of its previously marketed price range of $17 to $19 per share. This strong pricing has resulted in a post-offering market capitalization for Attovia of approximately $1.3 billion. The IPO, which saw 15.2 million shares offered, commenced trading on the Nasdaq under the ticker symbol 'ATTO'.

Goldman Sachs & Co. LLC, BofA Securities, and Evercore ISI served as the joint book-running managers for this significant offering, indicating substantial institutional interest and backing. Oppenheimer & Co. Inc. and S.D. Rabin & Co. LLC acted as co-managers. The substantial capital infusion secured by Attovia is strategically allocated to advance its lead drug candidate, ATTO-203, through its ongoing Phase 1 clinical trial. This trial is investigating ATTO-203's potential to treat systemic lupus erythematosus (SLE), a chronic and often debilitating autoimmune disease characterized by the immune system attacking its own tissues. Beyond ATTO-203, the funds will also support the development of Attovia's other pipeline programs, underscoring a commitment to a broader portfolio of innovative therapies.

Attovia also plans to utilize a portion of the proceeds for general corporate purposes, which include continued research and development activities, scaling up manufacturing capabilities, and exploring potential business development opportunities. The company's strategic focus on rare and severe immune-mediated diseases places it within a critical and growing segment of the biopharmaceutical market, where significant therapeutic advancements are urgently needed. Attovia's proprietary platform technology is designed to create highly targeted therapies that precisely modulate specific immune pathways, aiming for greater efficacy and reduced side effects compared to existing treatments. The successful completion of this IPO, with its strong valuation and significant funding, reflects a clear indication of investor confidence in Attovia's scientific rationale, its experienced management team, and its potential to address some of the most challenging diseases affecting the immune system. The substantial financial runway provided by this offering will enable Attovia to execute its ambitious clinical development strategy and further its vital research endeavors, ultimately aiming to deliver life-changing treatments to patients suffering from debilitating immune system disorders.